ERBB2 and breast cancer: A pilot study of 31 women with advanced HR+/HER2 negative BC commencing on a new line of palliative endocrine therapy showed that those with low baseline levels of plasma TKa had a median PFS of 25.9 months, vs. 5.9 months in those with high baseline levels (p = 0.012) (46).